tradingkey.logo

Apnimed Announces Positive Topline Results In The First Landmark Phase 3 Clinical Trial Of AD109, An Investigational Once-Daily Oral Pill For Obstructive Sleep Apnea

ReutersMay 19, 2025 10:12 AM

-

  • APNIMED ANNOUNCES POSITIVE TOPLINE RESULTS IN THE FIRST LANDMARK PHASE 3 CLINICAL TRIAL OF AD109, AN INVESTIGATIONAL ONCE-DAILY ORAL PILL FOR OBSTRUCTIVE SLEEP APNEA

  • APNIMED: AD109 MET PRIMARY ENDPOINT

  • APNIMED: EXPECTS TOPLINE RESULTS IN Q3'25 FROM SECOND PHASE 3 CLINICAL TRIAL, LUNAIRO, PLANS TO SUBMIT AN NDA TO U.S. FDA FOR AD109 BY EARLY 2026

  • APNIMED: AD109 GENERALLY WELL-TOLERATED & MOST COMMON ADVERSE EVENTS CONSISTENT WITH EARLIER AD109 CLINICAL TRIALS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI